Development of a novel approach for immunohistochemical assay validation



Keith Page, Jessica Petty, Mozam Ali, Sam Ho and Amanda Woodroofe

Asterand Bioscience, 2a Orchard Road, Royston Hertfordshire, UK & TechOne Suite 501, 440 Burroughs, Detroit MI USA

INTRODUCTION

Immunohistochemical (IHC) assays are increasingly used to detect protein biomarkers. For an IHC biomarker assay to be used to its maximal utility, assay development and validation are of paramount importance. Assay development and validation typically follows the guidelines set out in Validation of Analytical Procedures: Text and Methodology Q2(R1) and Q2B Validation of Analytical Procedures: Methodology. Assay validation can include quantification and while quantitative immunohistochemistryis performed, relative measures (i.e. relative optical density) are frequently used. In the analysis of human protein biomarkers, an approach has been developed which accelerates the progression of an IHC assay through assay validation (ICH Guidelines) and allows quantitation of antibody performance with reference to the physical concentration of the target protein. In the evaluation of this approach, we assessed the performance of two rabbit monoclonal antibodies to human Met (high-affinity tyrosine kinase receptor for hepatocyte growth factor) in standard IHC assays. Met was selected as the target for the case study due to the availability of antibodies, cell lines and full length recombinant, human protein.

SPECFICITY









Both D1C2 and EP1454Y generate staining intensities which correlate with concentration of spiked recombinant-MET.

APPROACH & METHODS

TARGET: Met, high-affinity tyrosine kinase receptor for hepatocyte growth factor (HGF). Altered Met expreession and phosphorylation state is found in several human cancers, including gastric, renal, colon and breast. **CELL LINES:**

| Met-ir | Cell Line | Reference |
|----------|---------------------|---|
| High | SNU5 gastric | SNU-5 (ATCC [®] CRL-5973™) |
| Moderate | HT29 colorectal | HT-29 (ATCC [®] HTB-38™) |
| Low | MB231 breast | MDA-MB-231 (ATCC [®] HTB-26 [™] |
| Absent | SNU1 gastric (mets) | SNU-1 (ATCC [®] CRL-5971™) |

ANTIBODIES:

Cell Signaling #8198 Met, Xp rabbit mAb-total Met, C-terminal D1C2 EP1454Y Abcam ab51067 rabbit mAb-total Met, N-terminal

PROTEINS:

ORIGENE TP317003

IHC VALIDATION ARRAY DESIGN:



Western and IHC analysis using D1C2 (panel A) more closely reflects the known levels of Met expression in the four cell lines. NSr data expresses the proportion of measured high-intensity pixels relative to all measured pixels.

QUALITATIVE ANALYSIS IN GASTRIC CANCER CORES



Digital scans (20X0 showing Met-ir in matched regions of one representative gastric carcinoma core. Two antigen retrievals (pH 6-9 and pH 9, shown) and five antibody concentrations (0.5mg/5mL shown) were tested. Non-immune rabbit IgGs 90.5mg/mL shown) and no primary negative controls (not shown) were run.

D1C2 Membrane staining in cancer cells **EP1454Y** Cytoplasmic plus membrane staining in cancer and mesenchymal cells

D1C2 limit of detection is 21.5mg/mL 'LIMIT' EP1454Y reatins non-specific staining throughout 'NS'

LINEARITY OF ASSESSED NSr: SPIKED HOMOGENATES



Using D1C2 at 0.5mg/mL, recombinant human Met is detectable to 2.5mg/mL. Staining intensity is linear across the measured range (2.5-20mg/mL, ANOVA F-99).



D1C2 demonstrates known cellular and sub-cellular expression



ARRAY HAS THREE KEY FEATURES

- 1. Cores from four cell lines with known levels of MET expression SNU5>HT29>MDAMB231>SNU1
- 2. Tissue array cores from gastric cancer (n=5 donors) Cellular and sub-cellular distribution
- 3. Spiked homogenates, 12 concentrations of recombinant human met
- Linearity, range, detection limits, etc

INTERMEDIATE PRECISION SNU5 **HT29** ss#1 Gastric 20mg/mL Cancer



SNU5

Gastric Spiked

LINEARITY ASSESSED USING NSr AND Met-ir IN SPIKED HOMOGENATES

Quantitation Limit IHC measurement determinable with quantitation Over measureable Met concentration range* Linearity Interval between lower and upper limits Range

2.5mg/ml, when [D1C2] used at 0.5mg/mL* Linear Regression: F-Test 99.2 (<5% significance) >2.5mg/mL to 20 mg/mL, when [D1C2] used at 0.5mg/mL*

REPEATABILITY

Six replicated assays



REPRODUCIBILITY SNU1 **HT29**



etana Atasa Interes 66138659 NSr SSE 30CHO

Meaurement of NSr in gastric cancer cores demonstrates higher level of between-slide variability



Example data demonstrating that analysis of human Met in the validation arrays is reproduced by two independent laboratories.



Images confirming assay precision between laboratories



Conclusions

- Custom validation arrays offer efficiences that can accelerate progression through IHC assay validation
- Combinations of cell lines, human tissues and spike homogenates provide complementary data
- Spiked homogenates analyzed using NSr generate informative and credible quantitative IHC data